Overview

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
A medicine that is FDA-approved for bone marrow stimulation (called Leukine) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
The Dana Foundation
Treatments:
Molgramostim
Sargramostim